Simulations Plus Releases New Simulation Software
- Share via
Simulations Plus Inc., a Lancaster-based developer of drug development simulation software for the pharmaceutical industry, has released Version 1.1.1 of its GastroPlus simulation software, used to predict the absorption of drugs by the human digestive system.
GastroPlus is currently licensed to eight pharmaceutical companies. The company has two other businesses, Words+ and FutureLab, which are based on its software technologies. The company trades on the NASDAQ under the symbol SIMU.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
